Kutatási jelek – Signal Engine

• Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2‑positive and HER2‑negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma — Gastric cancer
• Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma (MCL): Primary Analysis of the MCL Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study — Mantle cell lymphoma
• Progress in Acute Myeloid Leukaemia Treatment — Acute myeloid leukemia
• Perineal body squamous cell carcinoma treated with radical radiotherapy – a case report — Colorectal cancer
• Preclinical models in head and neck squamous cell carcinoma — Head and neck squamous cell carcinoma
• Nasopharyngeal carcinoma — Nasopharyngeal carcinoma
• Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment — Osteosarcoma
• Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer — Ovarian cancer
• Panitumumab vs Bevacizumab Added to Standard First-Line Chemotherapy and Overall Survival Among Patients With RAS Wild‑type, Left‑Sided Metastatic Colorectal Cancer — Colorectal cancer
• Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer — Colorectal cancer
• Targeting oncogenic KRAS in non‑small cell lung cancer with EGFR aptamer‑conjugated multifunctional RNA nanoparticles — NSCLC
• Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review — Colorectal cancer
• Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1 — Melanoma
• Top advances of the year: Melanoma — Melanoma
• Gastric cancer treatment: recent progress and future perspectives — Gastric cancer
• Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab — Gastric cancer
• Rethinking ovarian cancer III: the past decade and future directions — Ovarian cancer
• Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial — Lymphoma
• The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades — Lymphoma
• Investigation of EGFR and ALK mutation frequency and treatment results in advanced non‑small cell lung cancer — NSCLC